BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 16165184)

  • 1. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
    Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
    Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
    Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse neurotoxicity test for vaccinia-based smallpox vaccines.
    Li Z; Rubin SA; Taffs RE; Merchlinsky M; Ye Z; Carbone KM
    Vaccine; 2004 Mar; 22(11-12):1486-93. PubMed ID: 15063573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.
    García AD; Meseda CA; Mayer AE; Kumar A; Merchlinsky M; Weir JP
    Clin Vaccine Immunol; 2007 Aug; 14(8):1032-44. PubMed ID: 17596428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
    Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.
    Davies DH; Wyatt LS; Newman FK; Earl PL; Chun S; Hernandez JE; Molina DM; Hirst S; Moss B; Frey SE; Felgner PL
    J Virol; 2008 Jan; 82(2):652-63. PubMed ID: 17977963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
    Earl PL; Americo JL; Wyatt LS; Eller LA; Whitbeck JC; Cohen GH; Eisenberg RJ; Hartmann CJ; Jackson DL; Kulesh DA; Martinez MJ; Miller DM; Mucker EM; Shamblin JD; Zwiers SH; Huggins JW; Jahrling PB; Moss B
    Nature; 2004 Mar; 428(6979):182-5. PubMed ID: 15014500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
    Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
    Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
    Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of a numerically additive combined vaccine against tetanus and smallpox].
    Mayr A; Baljer G; Wagner C; Sailer J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein.
    Adamo JE; Meseda CA; Weir JP; Merchlinsky MJ
    J Gen Virol; 2009 Nov; 90(Pt 11):2604-2608. PubMed ID: 19587131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.